Análise dos transcritos da translocação t(9;22) em Leucemia Mielóide Crônica

Barboza, Luciana P.; Souza, Jorge Moreira de; Simões, Felippe V.; Bragança, Iracema C.; Abdelhay, Eliana

doi:10.1590/s1516-84842000000200005

Cited by 7 publications

(9 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding the main variables at diagnosis, results in our patient group are similar to those already published (Barboza et al, 2000;Bennour et al, 2013;Smith et al, 2014). In agreement with published data, our study showed a statistically significant association between the e14a2 transcript and high platelet count (Bennour et al, 2013), but also between the e13a2 transcript with high leukocyte count (Hanfstein et al, 2014).…”

Section: Discussionsupporting

confidence: 92%

BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia

Vasconcelos¹,

Azevedo²,

Melo³

et al. 2017

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. In chronic myeloid leukemia (CML) two main types of messenger RNA (e14a2 and e13a2) can be produced by BCR-ABL1 gene rearrangement. Due to conflicting results, the clinical value of these transcripts remains controversial. The aim of this study was to identify associations of e14a2 and e13a2 transcripts with laboratory variables and also the response to treatment. This study included 203 adult patients with CML treated with Imatinib as first-line drug in a reference hematology center in Northeast Brazil. Clinical and laboratory data were obtained after informed consent. Samples were collected for RNA extraction and analyzed by reverse transcription-polymerase chain reaction (PCR), according to the international protocol BIOMED-1. The LeukemiaNet 2013 criteria were used to establish the molecular response. The frequency distribution of the BCR-ABL1 transcripts was e14a2 (64%), e13a2 (34%), and double positives (2%). The results showed a statistically significant association of the e14a2 transcript type with thrombocytosis (P = 0.0005) and the e13a2 with higher leukocyte count (P = 0.0491). In a subgroup of 44 patients, the molecular response to treatment with Imatinib was assessed by quantitative PCR at 3 months (BCR-ABL1 ≤ 10%), 6 months (BCR-ABL1 ≤ 1%), or 12 months (BCR-ABL1 ≤ 0.1%). Although patients with the transcript e14a2 showed higher frequency of good responses than patients with the transcript e13a2, this difference was not statistically significant. In agreement with published data, our results showed association of the BCR-ABL1 transcript e14a2 with thrombocytosis and the BCR-ABL1 transcript e13a2 with higher leukocytosis in patients with chronic myeloid leukemia.

show abstract

Section: Discussionsupporting

confidence: 92%

BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia

Vasconcelos¹,

Azevedo²,

Melo³

et al. 2017

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…The reverse transcription-PCR technique is extremely sensitive, and can detect primary transcripts even at low levels of expression. Different types of BCR-ABL junctions are found in the diagnosis of CML, which fall into two main forms, b3a2 and b2a2, and two sporadic forms, e1a2 and e19a2 (Biernaux et al, 1995;Bose et al, 1998;Barbosa et al, 2000). In the present study, we were able to demonstrate the presence of BCR/ABL transcripts in healthy individuals even within a small sample size from south Brazil.…”

Section: Discussionsupporting

confidence: 57%

Analysis of BCR/ABL transcripts in healthy individuals

Boquett

Alves²,

Oliveira³

2013

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. The chimeric oncogene BCR/ABL, which is the product of reciprocal translocation between chromosomes 9 and 22, is a known molecular marker of chronic myeloid leukemia (CML), and is related to the major factors involved in leukemogenesis. Some previous studies have also reported the presence of this oncogene in peripheral blood cells of healthy individuals. In this study, we investigated the presence of BCR/ABL transcripts in peripheral blood of individuals aged 40 years or more without symptoms of CML. The presence of BCR/ABL transcripts was observed in 2 of the 30 individuals analyzed. The genesis of BCR/ABL transcripts and its presence in healthy individuals are topics of ongoing debate. The risks and biological implications of the presence of BCR/ABL transcripts in healthy individuals are challenging issues that remain to be elucidated.

show abstract

“…Ao diagnóstico, cerca de 90% dos pacientes apresentam um cariótipo marcador na maioria de suas metáfases em células de medula óssea: o cromossomo Ph. Em LMC Ph-positivo, a translocação é encontrada em todas as linhagens celulares hematopoiéticas, sendo menos freqüente em células B e T. 4 A LMC é mais freqüente em adultos entre 40 e 60 anos de idade e afeta ambos os sexos, mas com predominância no sexo masculino. A progressão clínica da LMC pode ser em três fases: crônica, acelerada e blástica.…”

Section: Introductionunclassified

“…A progressão clínica da LMC pode ser em três fases: crônica, acelerada e blástica. 4 O diagnóstico da LMC, seguindo as normas do Inca (Instituto Nacional de Câncer do Ministério da Saúde), é feito por meio da anamnese e do exame físico, do hemograma e da plaquetometria, da morfologia do sangue periférico, do mielograma, da citoquímica e da imunofenotipagem, da citogenética da medula óssea, da Reação em Cadeia da Polimerase qualitativa (pesquisa do marcador molecular BCR-ABL no sangue periférico ou na medula óssea), da biópsia de medula óssea, incluindo determinação de fibrose medular. 5 A progressão da LMC é usualmente associada à aquisição adicional de anormalidades citogenéticas, incluindo alterações envolvendo o braço curto do cromossomo 17 (17p).…”

Section: Introductionunclassified

Polimorfismo do gene tp53 no códon 72 em pacientes com suspeita de LMC

Hamú¹,

Oliveira²,

Silva³

et al. 2007

Rev. Bras. Hematol. Hemoter.

View full text Add to dashboard Cite

A leucemia mielóide crônica (LMC) é uma doença proliferativa do sistema hematopoiético, caracterizada pela expansão clonal de uma célula-tronco primitiva e pluripotente denominada stem cell. Este tipo de leucemia está associado, em 90% dos casos, à translocação t(9;22)(q34;q11). Essa alteração cromossômica estrutural codifica para uma proteína quimérica BCR-ABL, que confere às células leucêmicas uma alta resistência à morte, independente do agente indutor desse processo. A proteína p53 é uma reguladora transcricional induzida por danos no DNA, fato que resulta na parada do ciclo celular com conseqüente ativação de mecanismos de reparo ou mesmo na indução à apoptose. As mutações no gene TP53 são as alterações genéticas mais comuns em tumores malignos humanos. O presente estudo teve como objetivo genotipar e determinar a freqüência alélica do polimorfismo do TP53 no códon 72 (arginina -Arg e prolina -Pro), em pacientes com suspeita de LMC, pela Reação em Cadeia da Polimerase. Desta forma, os resultados indicaram que 73,4% (23/30) dos pacientes apresentaram homozigose para arginina (Arg/Arg) e 26,6% (7/30) heterozigose (Arg/ Pro). Não foi encontrado nenhum paciente homozigoto para prolina (Pro/Pro). Os resultados obtidos sugerem que o polimorfismo do gene TP53 no códon 72 não é um fator de risco importante para a iniciação, promoção e progressão da LMC. Rev. bras. hematol. hemoter. 2007;29(4):346-350. Palavras-chave:Leucemia mielóide crônica; LMC; polimorfismo; TP53.

show abstract

Análise dos transcritos da translocação t(9;22) em Leucemia Mielóide Crônica

Cited by 7 publications

References 6 publications

BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia

BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia

Analysis of BCR/ABL transcripts in healthy individuals

Polimorfismo do gene tp53 no códon 72 em pacientes com suspeita de LMC

Contact Info

Product

Resources

About